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Graphical abstract:
Solid-phase peptide synthesis of analogues of the N-terminus A-ring fragment of the lantibiotic
nisin: Replacements for the dehydroalanine (Dha) residue at position 5 and the first
incorporation of a thioamide residue
Kim Manzor, Keith ó Proinsias and Fintan Kelleher*
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Solid-phase peptide synthesis of analogues of the N-terminus A-ring fragment of the
lantibiotic nisin: Replacements for the dehydroalanine (Dha) residue at position 5 and
the first incorporation of a thioamide residue

Kim Manzor,1 Keith ó Proinsias2 and Fintan Kelleher1*

1. Molecular Design & Synthesis Group, Centre of Applied Science for Health, Institute of
Technology Tallaght, Dublin 24, Ireland
2. Polish Academy of Sciences, Institute of Organic Chemistry, Kasprzaka 44-52, PL01224 Warsaw, Poland

Abstract:
A number of A-ring analogues of the lantibiotic nisin, containing replacements for the Dha
at position 5, have been successfully prepared by solid-phase peptide synthesis. The Dha
replacements include glycine, alanine, phenylalanine, serine and 1-aminocyclopropyl
carboxylic acid (ACCa). The incorporation of a thioamide-isoleucine residue at position 4
is also described and is the first report of the preparation of a lantibiotic ring fragment
containing a thioamide link.

Keywords: Nisin; thioamide; microwave-enhanced solid-phase peptide synthesis;
lantibiotics; dehydroalanine

The lantibiotics are a class of ribosomally synthesised peptides which are subsequently
highly post-translationally modified.1 They are short peptides, with 19-34 amino acid
residues, and contain a number of unusual amino acids within their structures. Rather than
being linear peptides they contain a number of small cyclic motifs within their overall
structures formed by thioether linkages, as compared to the more common disulfide
linkages. The best known, and most studied, lantibiotic is nisin, which has been used as a
food preservative (E234) for over 50 years without the development of significant
antimicrobial resistance. It is produced by a Lactococcus lactis species and is highly active
against a wide-range of Gram-positive bacterial species including MRSA and the food3

borne pathogen Listeria monocytogenes. It is a 34 amino acid residue peptide with five
internal rings (A-E) within its overall sequence (Figure 1).
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Figure 1. The amino acid sequence of nisin A and the structures of its unusual amino acid
residues

The unusual amino acids present in nisin are dehydroalanine (Dha), dehydrobutyrine
(Dhb), lanthionine and -methyllanthionine. Of the 34 amino acids of nisin 13 are unusual,
which along with the fact that there are no aromatic amino acid residues present makes the
overall structure of nisin unique. The A-ring contains a lanthionine bridge (Ala-S-Ala)
while the remaining B-E rings contain -methyllanthionine bridges (Abu-S-Ala). Nisin is
both stable and soluble at acidic pH values having its maximum stability at pH 3-4.2
However, its stability and solubility decrease considerably at physiological pH which
precludes its use as a human therapeutic. The A and B rings of the N-terminus of nisin
(nisin3-12) are critical to its overall biological activity where it binds to the lipid II moiety
inhibiting the biosynthesis of the bacterial cell wall.3 It is known that at physiological pH
the two Dha residues at positions 5 and 33 are cleaved by hydrolysis.4 In particular
hydrolysis of Dha5 leads to opening of the A-ring which abolishes its biological activity,
while cleavage at Dha33 alone leads to a small drop in activity. A significant number of
structure-activity relationship studies on nisin involving mutagenesis have been undertaken
which show that it is possible to replace Dha5 while retaining activity.5 However, little is
known about how such amino acid mutations change the overall 3-D conformation of the
critical N-terminus region. NMR studies by the Murray group showed that the overall
4

conformation of the A-ring of nisin changed substantially when the Dha5 residue was
replaced by either a L-Ala or D-Ala moiety.6 For our studies one of the crucial aspects of
the endeavour would be the synthesis of useful A-ring analogues of nisin, where Dha5 has
been replaced, to study how changes affect both the conformations adopted and the
resulting stability of the peptides. Herein, the initial synthetic targets, where the
replacement of Dha5 with glycine, L-alanine, L-serine and L-phenylalanine residues is
described. The reasons for choosing these initial targets of amino acids were that i) glycine
would show the effect of removal of all rigidity at position 5; ii) L-alanine was the direct
analogue of Dha where the double bond was removed; iii) serine is a precursor to the Dha
moiety by dehydration and iv) phenylalanine is present at position 5 in the closely related
lantibiotics epidermin and gallidermin, which also bind to lipid II.1 A further analogue
targeted was the incorporation of a cyclopropyl group, which would require the use of 1aminocyclopropane carboxylic acid (ACCa). Since the Dha5 moiety is cleaved at
physiological pH leading to ring-opening and complete loss of biological activity, it is
postulated that the cyclopropyl group would be a more hydrolytically stable mimic of the
Dha group, while keeping the overall conformation of the peptide ring. Furthermore, it is
known that the group can interact through hyperconjugation with a carbonyl group, in a
manner akin to a vinyl group.7 The N-C-C(=O) bond angle of the ACCa is usually close
to 116o,6 which is closer to the theoretical 120o of the sp2 hybridised system of the Dha
than the tetrahedral bond angle of 109.5o (Figure 2).
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Figure 2. N-C-C(=O) bond angles for Dha, ACCa and Ala

The proposed Dha5 replacements will ultimately give a greater understanding of how and
why structural changes in that region might impact the overall biological activity.

Previously lantibiotics have been prepared by solid-phase peptide synthesis (SPPS),
including epilancin X,8 lacticin 3147a and 3147b,9 and Cytolysin.10 These syntheses
5

required the reliable preparation of significant quantities of orthogonally protected
lanthionines and -methyllanthionines with tailored protecting groups suitable for SPPS.

Lanthionine Synthesis
Although a wide number of methods are published for the synthesis of orthogonally
protected lanthionines11 we found that a variation of the methods described by Schmidt,12
and van der Donk,8 using phase-transfer catalysis, to be the most reproducible and high
yielding. Thus the two coupling partners, bromoalanine 1 and cysteine 2 were prepared and
used immediately due to their instability over time and upon exposure to air. The reaction
was conducted in a degassed mixture of ethyl acetate and aqueous sodium hydrogen
carbonate in the presence of tetrabutylammonium bromide at pH 8.5. Wavering from these
precise conditions, i.e., not sufficiently degassing the reaction mixture nor maintaining it at
exactly pH 8.5, resulted in very low isolated yields of 3, due to oxidation of 2 to the
cystine, and/or the formation of significant amounts of a diastereoisomer of 3. Thus,
orthogonally protected lanthionine 3 was successfully prepared in an isolated yield of 55%
(based on bromoalanine 1) as a single diastereoisomer (Scheme 1). Subsequent
deprotection of the t-butyl ester gave the desired lanthionine 4, ready for use in SPPS.
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Scheme 1. Synthesis of orthogonally protected lanthionine 47,11

Preparation of the nisin A-ring analogues by SPPS
Having successfully obtained orthogonally protected lanthionine 4 it was then used for
preparation of a number of analogues of the A-ring of nisin by SPPS. The resin chosen for
SPPS was a 2-chlorotrityl chloride resin (1.33 mmol/g loading) because of its successful
use by Vederas for the synthesis of both components of lacticin 3147.9 The preparation of
the analogue containing a glycine in place of Dha5, i.e. Dha5Gly, is exemplified in Scheme
6

2. The other analogues were prepared using similar methodology. Lanthionine 4 was first
coupled to the resin to give a reduced loading of 0.16 mmol/g,9 with the remaining reactive
sites being capped with acetic acid. A Kaiser test showed the absence of free NH2 groups.13
The Fmoc group of the resin-loaded lanthionine 5 was efficiently removed using 20%
piperidine in DMF using microwave enhancement at 50 oC for 10 min. Coupling was
undertaken using a pre-activated solution of Fmoc leucine (5 molar equivalents), PyBOP (5
molar equivalents), HOBt (5 molar equivalents) and N-methylmorpholine (5.5 molar
equivalents), using microwave enhancement at 75 oC for 10 min, to give peptide 6.
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Scheme 2. Synthesis of nisin A-ring analogues (12-16), with position Dha5 modified
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This loaded resin was then split into five equal portions for the synthesis of the target
analogues. Separately, Fmoc

L-alanine,

Fmoc glycine, Fmoc

L-serine,

Fmoc

L-

phenylalanine and Fmoc ACCa were successfully coupled using the same coupling
protocol, followed by deprotection and the final coupling of Fmoc L-isoleucine to give
peptides 7-11. Removal of the two allyl based protecting groups was achieved by treatment
with Pd(PPh3)4 in DCM/DMF (50:50), in the presence of phenylsilane as a scavenger.
Subsequent cyclisation on the resin using PyBop (5 molar equivalents), HOBt (5 molar
equivalents) and N-methylmorpholine (5.5 molar equivalents), using the method of Vederas,14
gave the five analogues (12-16) of the nisin A-ring, as confirmed by HRMS analysis after
cleavage from the resin using TFA (See Table 1 in Supporting Information).

Incorporation of a thioamide residue at position 4 (isoleucine) of the A-ring of nisin
As part of its mechanism of action nisin is known to bind to the pyrophosphate moiety of
lipid II, which is present in the bacterial cell wall, through five key H-bonding interactions
of the N-H protons of the A and B rings.15 One of these key interactions involves the N-H
of the Dha5 residue of the A-ring.
It is known that thioamides are significantly better H-bond donors than their amide
counterparts,16 therefore, we envisaged that replacement of Ile4 with thioamide-Ile4 would
lead to stronger H-bonding to the pyrophosphate moiety. In order to achieve this goal
thioamide dipeptide 18 must be synthesised followed by incorporation into the A-ring,
using methods employed for the amide analogues 12-16. We have recently reported the
efficient synthesis of such dipeptides via the selective thionation of the amide group of
protected dipeptides,17 using Curphey’s method.18
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Coupling of the deprotected thioamide dipeptide 19 to resin-loaded peptide 6, which had
been firstly deprotected with 20% piperidine in DMF, gave thioamide peptide 20.
Subsequent deprotection and cyclisation gave the cyclised peptide 21 (Table 1). This is the
first report of the successful preparation of a lanthionine-containing ring peptide fragment
incorporating a thioamide link.

Peptide isolation and purification
All of the peptides prepared are very hydrophobic in nature and although HRMS analysis
of the cleaved product from a small amount of resin showed that the correct cyclic peptides
had been formed, there are challenges in the isolation, solubilisation and purification of
these peptides. Use of a wide range of published methods for the isolation of hydrophobic
peptides, has so far not been fully successful. It is after cyclisation and full cleavage from
9

the resin when the solubility problems arise and work is continuing on addressing these
issues. However, post cleavage from the resin there is no evidence for any uncyclised
peptides remaining by MS analysis, which strongly suggests that cyclisation has
successfully occurred, as seen for other related literature syntheses.8-10,19

Conclusions
For the purpose of investigating the impact of alteration of the reactive Dha5 residue of the
A-ring of nisin has on the conformation of the peptide a series of analogues were
synthesised on a small scale using SPPS in order to examine and optimise the synthetic
route. Firstly, using phase transfer reaction conditions with a suitably protected
bromoalanine (1) and cysteine (2) the desired lanthionine 4, a templete for the A-ring, was
isolated in 55% yield, as a single diastereoisomer. Using microwave assisted SPPS a
collection of useful A-ring analogues, in which the Dha5 was replaced with Gly, Ala, Ser,
Phe or ACCa, were successfully prepared. Furthermore, in order to enhance binding to
lipid II, Ile4 of the A-ring was successfully replaced with the significantly better H-bond
donor thioamide-Ile4 while incorporating Phe at position 5 in place of Dha. Other
thioamide-containing A-ring analogues are now being targeted of the key H-bond donors
for the binding interaction with the pyrophosphate moiety of lipid II.15,16 Scale-up of the
syntheses is currently being undertaken, along with the optimisation of the purification of
all the peptides. Detailed NMR studies of all of these peptides will then be undertaken to
examine the effects of replacing Dha5 and incorporation of thioamide moieties on the
solution conformations. The results of these studies will be reported in due course.
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Solid-phase peptide synthesis of analogues of the N-terminus A-ring fragment of the
lantibiotic nisin: Replacements for the dehydroalanine (Dha) residue at position 5 and
the first incorporation of a thioamide residue

Kim Manzor,1 Keith ó Proinsias2 and Fintan Kelleher1*

1. Molecular Design & Synthesis Group, Centre of Applied Science for Health, Institute of
Technology Tallaght, Dublin 24, Ireland.
2. Polish Academy of Sciences, Institute of Organic Chemistry, Kasprzaka 44-52, PL01224 Warsaw, Poland

Experimental Methods

General Methodology
IR spectra were recorded on a Nicolet Impact 410 FT-IR and characteristic stretches are
reported. Solid samples were prepared as dispersions in KBr discs and liquid samples as a
film between sodium chloride plates. NMR spectra were obtained on a Bruker Avance III
300 spectrometer operating at 300 MHz for 1H spectra. The typical resolution of this
machine is 0.095 Hz or 0.000315 ppm, while coupling constant (J) values are accurate to ±
0.19 Hz. For

13

C spectra it operates at 75 MHz, with a typical resolution of 0.28 Hz or
12

0.0037 ppm. NMR spectra were also obtained on a Bruker Avance III 500 spectrometer
operating at 500 MHz for 1H NMR. The typical resolution of this machine is 0.11 Hz or
0.00022 ppm, while coupling constant (J) values are accurate to ± 0.22 Hz. For 13C spectra
it operates at 125 MHz, with a typical resolution of 0.45 Hz or 0.0036 ppm. The 300 MHz
spectrometer was used unless otherwise stated. 1H NMR and

13

C NMR assignments were

achieved with the aid of the following: DEPT (90 and 135), COSY, HSQC, and HMBC.
All solvents used were purchased from Sigma Aldrich or Lennox Chemicals. Solvents
were dried and stored in accordance with literature procedures.1 Petroleum ether 40-60 was
used for all synthesis and purification methods. High Resolution Mass Spectrometry was
performed on an Agilent Technologies 6530 Accurate-Mass Q-TOF LC/MS, utilising the
Mass-Hunter workstation software. Samples were dissolved in HPLC grade acetonitrile,
with volumes injected onto the system of between 0.5–2.0 μL. The mobile phase (all
HPLC grade) used was acetonitrile (70%), water (30%), and formic acid (0.1%). A flowrate of 0.5 mL/min of mobile phase was used, while the column in the LC component was
a C18 column. UV analysis was performed using a Hitachi U-2900 double beam
spectrophotometer. Thin layer chromatography was performed using Merck aluminiumbacked sheets with silica gel 60 F254. Isolated products were purified using flash
chromatography with silica gel (0.040-0.0063 mm, 230-400 mesh) obtained from VWR.
Polarimetry was carried out at room temperature using a 1 dm optical activity tube and an
AA-55 Optical Activity Ltd. Polarimeter. Microwave synthesis was conducted using a
CEM Focused Microwave Synthesis System, using a Discover SPS manual microwave
peptide synthesiser attachment which included a 25 mL reaction vessel, a reaction vessel
holder, a vacuum manifold, and a fiber-optic temperature probe. The manifold consists of
two separate fluid paths for both waste and product collection under vacuum.

General Synthetic Methods
1. General procedure for coupling using Fmoc solid-phase peptide synthesis
(SPPS)
A coupling solution of Fmoc-protected amino acid (5 molar equivalents to resin loading),
HOBT (5 molar equivalents), PyBOP (5 molar equivalents) and N-methylmorpholine (5.5
molar equivalents) in DMF was prepared and allowed to pre-activate for 5 min. The
solution was transferred to the peptide reaction vessel containing pre-swelled resin (DCM
for 30 min.). The reaction vessel was placed in the microwave reactor and heated to 75 oC
(50 W) for 10 min. The reaction vessel was then cooled to room temperature and was
13

shaken for a further 20 min., while nitrogen was gently bubbled through the solution. The
resin was washed with DMF (3 x 10 mL) and DCM (3 x 10 mL). A small sample of resin
was taken after each coupling step and the peptide was cleaved from the resin (see below)
and analysed by LC-MS.

2.

General procedure for peptide cleavage from the resin

A small sample of resin was taken and peptide cleavage was achieved by treatment with
TFA:anisole:H2O (95:5:5) and shaking for 1 h, without microwave assistance. The resin
was removed by filtration and the filtrate was concentrated in vacuo. The resulting residue
was dissolved in acetonitrile and analysed by HRMS to determine the content.

3.

General procedure for Fmoc deprotection

The N-terminal Fmoc protecting group was deprotected by the addition of 20% piperidine
in DMF (10 mL) to the peptide reaction vessel. The reaction vessel was placed in the
microwave reactor and heated to 50 oC (25 W) for 10 min. The resin was cooled to room
temperature and washed with DMF (3 x 10 mL) and DCM (3 x 10 mL). The deprotection
filtrate solution was taken and analysed by UV spectrophotometry, where the presence of
the dibenzofulvene-piperidine adduct at 301 nm determined if the deprotection step was
successful.

4.

General procedure for the removal of a t-butyl ester group

To the protected compound (1.0 mmol) was added DCM (5 mL), TFA (5 mL), and
phenylsilane (0.13 mL, 0.11 g, 1.1 mmol) and the reaction was stirred for 2 h in an icebath, under a nitrogen atmosphere. The reaction was monitored by MS until the molecular
ion peak of the starter was no longer present. The reaction mixture was then concentrated
in vacuo and repeatedly redissolved in DCM and concentrated in vacuo to remove residual
TFA.

Syntheses
Synthesis of allyl (S)-(1-[(allyloxy)carbonyl)]-N-(2-bromoethyl)carbamate (1). D-Serine
(1.00 g, 9.51 mmol) and Na2CO3 (1.05 g, 9.90 mmol) were dissolved in water (10 mL) and
acetonitrile (5 mL) was added followed by the dropwise addition of allyl chloroformate
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(1.05 mL, 1.19 g, 9.88 mmol) over 5 min. The mixture was stirred for 30 h, at room
temperature, before being concentrated to dryness in vacuo. The residue was then
dissolved in dry DMF (20 mL) and NaHCO3 (0.82 g, 9.8 mmol) was added followed by
the dropwise addition of allyl bromide (0.85 mL, 1.19 g, 9.8 mmol) over 5 min. The
mixture was stirred for 45 h at room temperature and then concentrated in vacuo. The
residue was dissolved in ethyl acetate (50 mL) and washed with a saturated aqueous
NaHCO3 solution (40 mL), water (3 x 40 mL), and brine (2 x 30 mL). The organic layer
was dried over anhydrous MgSO4 and concentrated in vacuo to afford a yellow oil.
Purification by flash chromatography on silica in petroleum ether:ethyl acetate (3:2) gave
allyl (R)-1-[(allyloxy)carbonyl)]-N-(2-hydroxyethyl)carbamate as a pale yellow oil (1.52 g,

70%). [α]D20: +2.96 (c = 1.35 in CHCl3); Rf 0.56, petroleum ether:ethyl acetate (2:1); 1H
NMR (CDCl3) δ/ppm; 6.21 (d, 1H, J = 8.3 Hz), 5.94-5.86 (m, 2H), 5.25-5.19 (m, 4H),
4.67-4.64 (m, 4H), 4.44-4.41 (m, 1H), 3.98 (dd, 1H J = 11.5 and 3.7 Hz), 3.86 (dd, 1H J =
11.5 and 3.4 Hz); 13C NMR (CDCl3) δ/ppm; 163.1, 156.2, 132.5, 131.5, 118.4, 117.6, 66.4,
65.8, 62.6, 56.1; IR (Thin Film, NaCl)/cm-1; 3404, 2949, 1722, 1689, 1645, 1320; HRMS:
ES+ for C10H15NO5, expected [M+H]+ 230.1028, observed [M+H]+ 230.1024.
To a solution of allyl (R)-1-[(allyloxy)carbonyl)]-N-(2-hydroxyethyl)carbamate (0.50 g,
2.2 mmol) and CBr4 (1.24 g, 3.7 mmol) in dry DCM (5 mL) at 0 oC was added PPh3 (1.17
g, 4.44 mmol) portionwise over a 5 min period. The mixture was then stirred at room
temperature for 2.5 hr, after which it was concentrated in vacuo. Purification by flash
chromatography on silica gel in petroleum ether:ethyl acetate (4:1) gave 1 as a clear oil
(0.40 g, 63%). Rf 0.75, petroleum ether:ethyl acetate (2:1); 1H NMR (CDCl3) δ/ppm; 5.955.82 (m, 2H), 5.35-5.17 (m, 4H), 4.81-4.75 (m, 1H), 4.68-4.55 (m, 4H), 3.79 (dd, 1H, J =
10.6 and 3.4 Hz), 3.68 (dd, 1H, J = 10.6 and 3.5 Hz);
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C NMR (CDCl3) δ/ppm; 163.5,

152.9, 132.2, 131.3, 118.9, 118.3, 67.0, 66.5, 65.0, 60.8; IR (Thin film, NaCl)/cm-1; 3338,
2947, 1724, 1649, 1519, 1333, 665; HRMS: ES+ for C10H14NO4Br, expected [M+Na]+
314.0001, observed [M+Na]+ 314.0003.

Synthesis

of

N-(9H-fluorenylmethyloxycarbonyl)-(R)-cysteine

t-butyl

ester

(2).

Tributylphosphine (0.50 mL, 0.41 g, 2.0 mmol) was added to a solution of N-(9Hfluorenylmethyloxycarbonyl)-(R)-cystine t-butyl ester2 (1.50 g, 1.88 mmol) in THF (20
mL) under a nitrogen atmosphere and the solution was stirred for 15 min. Water (2.0 mL)
was added and the reaction was stirred for an additional 2.5 h. The reaction was
15

concentrated in vacuo yielding 2 as a clear oil (1.09 g, 72%). The product was used
immediately after preparation due to its instability. 1H NMR (CDCl3) δ/ppm; 7.72 (d, 2H,
J = 7.5 Hz), 7.53 (d, 2H, J = 7.5 Hz), 7.40 (dd, 2H, J = 7.3 and 7.5 Hz), 7.29 (dd, 2H, J =
6.9 and 7.3 Hz), 5.70 (d, 1H, J = 7.4 Hz), 4.55-4.45 (m, 1H), 4.58-4.33 (m, 2H), 4.20 (dd,
1H, J = 8.9 and 6.5 Hz), 3.03-2.93 (m, 2H), 1.48 (s, 9H); IR (Thin Film, NaCl) cm-1; 3334,
3064, 2978, 2570 (S-H), 1731, 1605.

Synthesis of 3-[2-(R)-allyloxycarbonyl-2-allyloxycarbonylamino-ethylsulfanyl]-2-(S)-(9Hfluorenylmethyloxycarbonylamino)propionic acid t-butyl ester (3). Cysteine 2 (1.06 g, 2.7
mmol) and β-bromoalanine 1 (0.82 g, 2.8 mmol) were both dissolved in degassed ethyl
acetate (15 mL), under a nitrogen atmosphere. A solution of tetrabutylammonium bromide
(3.55 g, 10.0 mmol) dissolved in a saturated aqueous NaHCO3 solution (15 mL, pH 8.5)
was then added to the mixture, which was stirred vigorously for 18 h (both the ethyl
acetate and NaHCO3 solution were deoxygenated by bubbling nitrogen gas into each
solution for 30 min). Ethyl acetate (15 mL) and H2O (15 mL) were added to the mixture
and the organic layer was separated, dried over anhydrous MgSO4 and concentrated in
vacuo. Purification by flash chromatography on silica gel in petroleum ether: ethyl acetate
(4:1) gave 3 as a clear oil (0.89 g, 55%). [α]D20: -6.25 (c = 0.32 in CHCl3); Rf 0.28, 3:1
petroleum ether:ethyl acetate; 1H NMR (CDCl3) δ/ppm; 7.72 (d, 2H, J = 7.4 Hz), 7.63-7.54
(m, 2H), 7.39-7.34 (m, 2H), 7.31-7.26 (m, 2H), 5.92-5.79 (m, 2H), 5.77 (d, 1H, J = 7.5
Hz), 5.69 (d, 1H, J = 7.5 Hz), 5.31-5.15 (m, 4H), 4.61-4.55 (m, 4H), 4.52-4.46 (m, 2H),
4.40-4.33 (m, 2H), 4.24-4.19 (m, 1H), 3.07-2.94 (m, 4H), 1.46 (s, 9H); 13C NMR (CDCl3)
δ/ppm; 170.1, 169.3, 155.7, 155.6, 143.7, 141.2, 132.2, 131.2, 127.6, 126.9, 125.0, 119.8,
119.0, 117.7, 82.8, 67.1, 66.2, 65.8, 54.6, 53.8, 46.9, 35.7, 35.6, 27.8; IR (Thin Film,
NaCl)/cm-1; 3066, 2948, 1724, 1700, 1536; HRMS: ES+ for C32H38N2O8S, expected
[M+Na]+ 633.2266, observed [M+Na]+ 633.2269.

Synthesis of 3-[2-(R)-allyloxycarbonyl-2-allyloxycarbonylamino-ethylsulfanyl]-2-(S)-(9Hfluorenylmethyloxycarbonylamino)propionic acid (4). Lanthionine 3 (0.40 g, 0.66 mmol)
was deprotected using the general method described. Purification by flash chromatography
on silica gel eluting with dichloromethane:methanol (98:2) gave 4 as a pale yellow oil
(0.32

g,

86%).

[α]D20:

+14.47

(c

=

0.76

in

CHCl3);

Rf

0.19,

dichloromethane:methanol:acetic acid (25:1:0.1); 1H NMR (CDCl3) δ/ppm; 8.93 (s (br),
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1H), 7.75 (d, 2H, J = 7.5 Hz),7.63-7.49 (m, 2H),7.42-7.34 (m, 2H), 7.32-7.27 (m, 2H),
6.03 (d, 1H, J = 7.9 Hz), 5.96-5.78 (m, 2H), 5.35-5.15 (m, 4H), 4.62-4.56 (m, 6H, J = 17.2
and 5.6 Hz), 4.43-4.31 (m, 2H), 4.25-4.19 (m, 1H), 3.13-2.78 (m, 4H); 13C NMR (CDCl3)
δ/ppm; 173.2, 170.4, 156.3, 156.1, 143.7, 141.4, 132.3, 131.3, 127.9, 127.2, 125.2, 120.1,
119.5, 118.3, 67.6, 66.7, 66.4, 54.1, 53.7, 47.1, 35.5, 35.4; IR (Thin film, NaCl)/cm-1;
3400, 3318, 3051, 2947, 2935, 1725, 1700; HRMS: ES+ for C28H30N2O8S, expected
[M+H]+ 555.1801, observed [M+H]+ 555.1796.

Preparation of lanthionine-loaded resin 5. 2-Chlorotrityl chloride resin (2.0 g, 1.3 mmol/g
loading) was pre-swelled in DCM (20 mL) with gentle shaking for 30 min. A loading
solution of orthogonally protected lanthionine 4 (0.18 g, 0.32 mmol) and DIPEA (0.28 mL,
0.21 g, 1.60 mmol) in DCM (20 mL) was added to the resin in a peptide reaction vessel
and the mixture was stirred gently for 2.5 h. The solution was filtered from the resin and
the resin was then washed with DCM (3 x 20 mL). The remaining reactive sites on the
resin were then capped using a solution of acetic acid (0.11 ml, 0.12 g, 2.0 mmol) and
DIPEA (1.39 ml, 1.03 g, 8.00 mmol) in DCM (20 mL) for 2 h with gentle shaking, while
N2 was bubbled through the mixture. The resin was washed with DCM (3 x 20 mL). This
gave a resin with a reduced loading (0.16 mmol/g) which was ready for SPPS. The Kaiser
test3 was carried out on a few resin beads which confirmed there were no primary amines
present. A sample of the resin 5 was taken and cleaved using the general procedure (see
above) and analysed by MS. HRMS: ES+ for C28H30N2O8S, expected [M+H]+ 555.1801,
observed [M+H]+ 555.1808.

Preparation of Fmoc-Ile-Phe t-butyl ester 17. To an ice-cold slurry of Fmoc-L-isoleucine
(0.71 g, 2.0 mmol) and and L-phenylalanine t-butyl ester (0.44 g, 2.0 mmol) in acetonitrile
(10 ml) was added Et3N (0.6 ml, 0.44 g, 4.2 mmol) and HBTU (0.9 g, 2.2 mmol) and the
reaction mixture was stirred at room temperature for 2 hr. The mixture was concentrated
under reduced pressure and the residue was taken up in EtOAc and washed with HCl (2 M,
10 ml), a saturated aqueous NaHCO3 solution (10 ml), dried over anhydrous MgSO4, and
concentrated in vacuo. Purification by flash column chromatography on silica gel eluted
with petroleum ether:ethyl acetate (4:1) gave 17 as a white solid (1.08 g, 97%). Rf 0.67,
petroleum ether:ethyl acetate (2:1); M.pt. 136-137 oC; [α]D20: -20.00 (c = 0.10 in CHCl3);
1

H NMR (CDCl3) δ/ppm; 7.75 (d, 2H, J = 7.4 Hz), 7.59 (d, 2H, J = 7.4 Hz), 7.42-7.35 (m,

2H), 7.33-7.27 (m, 2H), 7.24-7.12 (m, 5H), 6.21 (d, 1H, J = 7.4 Hz), 5.34 (d, 1H, J = 8.8
17

Hz), 4.74 (dd, 1H, J = 7.3 and 6.2 Hz), 4.46-4.35 (m, 2H), 4.26-4.19 (m, 1H), 3.4.18-4.15
(m, 1H), 3.07 (d, 2H, J = 6.2 Hz), 1.88-1.79 (m, 1H), 1.51-1.45 (m, 1H), 1.39 (s, 9H),
1.18-1.04 (m, 1H), 0.91-0.86 (m, 6H);
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C NMR (CDCl3) δ/ppm; 170.6, 170.2, 156.2,

143.9, 141.4, 135.5, 129.5, 128.4, 127.8, 127.2, 127.1, 125.2, 120.0, 82.6, 67.1, 59.7, 53.6,
47.2, 38.2, 37.6, 27.9, 24.8, 15.4, 11.4; IR (KBr)/cm-1; 3309 (N-H), 3089 (C-H, aromatic),
2965 (C-H, aliphatic), 1735 (C=O, ester), 1700 (C=O, carbamate), 1655 (C=O, amide);
HRMS: ES+ for C34H40N2O5, expected [M+K]+ 595.2574, observed [M+K]+ 595.2571.
Preparation of Fmoc-Ile(C=S)-Phe t-butyl ester 18. To a solution of 17 (0.60 g, 1.1
mmol)) in dry DCM (20 ml) was added P2S5 (0.60 g, 1.1 mmol) followed by
hexamethyldisiloxane (HMDO) (1.2 ml, 0.92 g, 5.5 mmol) and the reaction mixture was
stirred at reflux temperature under an atmosphere of nitrogen for 5 hr. A further molar
equivalent of P2S5 and 5 molar equivalents of HMDO was then added and the mixture was
heated at reflux temperature and monitored by TLC until the reaction went to completion.
The solution was concentrated in vacuo and the resulting residue was dissolved in EtOAc,
washed with water (2 x 15 ml), brine (20 ml) and dried over anhydrous MgSO4.
Purification on silica gel eluting with petroleum ether:ethyl acetate (4:1) gave the desired
thioamide as a clear oil (0.59 g, 96%). Rf 0.81, petroleum ether:ethyl acetate (2:1); Oil;
[α]D20: +47.22 (c = 0.36 in CHCl3); 1H NMR (CDCl3) δ/ppm; 8.35 (d, 1H, J = 6.3 Hz),
7.76-7.71

(m, 2H), 7.60 (d, 2H, J = 7.3 Hz), 7.40-7.34 (m, 2H), 7.32-7.26

(m, 2H),

7.24-7.10 (m, 5H), 5.63 (d, 1H, J = 8.6 Hz),5.30-5.23 (m, 1H), 4.46-4.28 (m, 2H),

4.26-

4.18 (m, 2H), 3.21 (d, 2H, J = 6.2Hz), 1.99-1.81 (m, 1H), 1.65-1.53 (m, 1H), 1.37 (s, 9H),
1.18-1.06 (m, 1H), 0.92-0.85 (m, 6H);
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C NMR (CDCl3) δ/ppm; 204.1, 169.5, 156.1,

144.0, 140.4, 135.6, 129.7, 128.6, 127.9, 127.3, 127.3, 125.3, 119.9, 82.2, 67.2, 66.2, 58.9,
47.2, 39.7, 36.6, 28.0, 24.8, 15.8, 11.5; IR (Thin film, NaCl)/cm-1; 3276 (N-H), 3064 (C-H,
aromatic), 2967, 2933 (C-H, aliphatic), 1728 (C=O, ester), 1693 (C=O, carbamate), 1031
(C=S, thioamide); HRMS: ES+ for C34H40N2O4S, expected [M+Na]+ 595.2606, observed
[M+Na]+ 595.2572.

Preparation of Fmoc-Ile(C=S)-Phe 19. To 18 (0.18 g, 0.33 mmol) was added DCM (1.5
ml), TFA (1.5 ml), and phenylsilane (0.04 ml, 0.033 g, 0.33 mmol) and the reaction was
stirred for 2 hr. in an ice-bath, under an atmosphere of nitrogen. The reaction was
monitored by LC-MS until the molecular ion peak of the starter was no longer present and
this indicated the reaction had gone to completion. The reaction mixture was then
18

concentrated in vacuo and repeatedly redissolved in DCM and concentrated in vacuo to
remove residual TFA. The product was purified by flash chromatography on silica gel
eluting with dichloromethane:methanol (98:2) to yield 19 as a pale yellow oil (0.16 g,
90%). Rf 0.07, ethyl acetate:petroleum ether (2:1); 1H NMR (CDCl3) δ/ppm; 8.92 (s, 1H),
7.76 (d, 2H, J = 7.6 Hz), 7.51-7.56 (m, 2H), 7.51-7.35 (m, 2H), 7.34-7.28 (m, 2H), 5.87 (d,
1H, J = 10.0 Hz), 4.89-4.64 (m, 1H), 4.52-4.45 and 4.35-4.29 (m, 2H), 4.35-4.22 (m, 2H),
4.19-4.13 (m, 1H), 3.75 (s (br), 1H), 1.86-1.75 (m, 1H), 1.72-1.46 (m, 1H),
1H), 0.93-0.87 (m, 6H).
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1.19-1.15 (m,

C NMR (CDCl3) δ/ppm; 204.4, 170.9, 156.6, 143.5, 141.3,

127.8, 127.1, 125.1, 120.1, 67.6, 64.4, 47.3, 47.0, 40.7, 25.2, 15.5, 10.7; IR (KBr)/cm-1,
3290 (O-H), 3066 (C-H, aromatic), 2965, 2927 (C-H, aliphatic), 1706 (C=O, acid), 1696
(C=O, carbamate), 908 (C=S, thioamide); HRMS: ES+ for C23H26N2O4S, expected [M+H]+
427.1691, observed [M+H]+ 427.1702.

Peptide

Molecular Formula

HRMS (Observed)

HRMS (Expected)

4

C28H30N2O8S

555.1796 [M+H]+

555.1801[M+H]+

7

C43H57N5O11S

852.3853 [M+H]+

852.3829 [M+H]+

8

C42H55N5O11S

838.3697 [M+H]+

838.3692 [M+H]+

9

C43H57N5O12S

890.3634 [M+Na]+

890.3634 [M+Na]+

10

C49H61N5O11S

928.4166 [M+H]+

928.4161 [M+H]+

11

C44H57N5O11S

864.3853 [M+H]+

864.3850 [M+H]+

12

C20H35N5O6S

474.2378 [M+H]+

474.2386 [M+H]+

13

C21H37N5O6S

488.2545 [M+H]+

488.2542 [M+H]+

14

C21H37N5O7S

504.2491 [M+H]+

504.2508 [M+H]+

15

C27H41N5O6S

564.2855 [M+H]+

564.2855 [M+H]+

16

C22H37N5O6S

500.2542 [M+H]+

500.2555 [M+H]+

17

C34H40N2O5

595.2571 [M+K]+

595.2574 [M+K]+

18

C34H40N2O4S

595.2606 [M+Na]+

595.2572 [M+Na]+

19

C30H32N2O4S

517.2161 [M+H]+

517.2169 [M+H]+

20

C49H61N5O10S2

966.3757 [M+Na]+

966.3755 [M+Na]+

21

C27411N5O15S2

597.2892 [M+NH4]+

597.2874 [M+NH4]+

Table 1. High-Resolution MS results for all synthesised peptides.
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